News & SEC Filings

View the latest news and SEC filings

News

Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m.

PDUFA Target Action Date for Ensifentrine of June 26, 2024  Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT /…

Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) — Verona Pharma…

PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and…

SEC Filings

Date Form Filing Group

April 30, 2024

Report of unscheduled material events or corporate event

8-K

Current Reports

April 2, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

March 20, 2024

An annual report to security holders

ARS

Annual Filings

March 20, 2024

Official notification to shareholders of matters to be brought to a vote (“Proxy”)

DEF 14A

Proxy Filings

March 12, 2024

Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

144

Other

March 8, 2024

A preliminary proxy statement providing notification matters to be brought to a vote

PRE 14A

Proxy Filings

March 7, 2024

Initial filing by director officer or owner of more than ten percent

3

3,4,5

March 4, 2024

Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

144

Other

February 29, 2024

Annual report which provides a comprehensive overview of the company for the past year

10-K

Annual Filings

Developing novel therapeutics for respiratory diseases

Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.